Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Scot Sedlacek to Antineoplastic Combined Chemotherapy Protocols

This is a "connection" page, showing publications Scot Sedlacek has written about Antineoplastic Combined Chemotherapy Protocols.

 
Connection Strength
 
 
 
0.306
 
  1. Osborne C, Challagalla JD, Eisenbeis CF, Holmes FA, Neubauer MA, Koutrelakos NW, Taboada CA, Vukelja SJ, Wilks ST, Allison MA, Reddy P, Sedlacek S, Wang Y, Asmar L, O'Shaughnessy J. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer. Clin Breast Cancer. 2018 02; 18(1):e89-e95.
    View in: PubMed
    Score: 0.065
  2. Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Lindquist DL, Holmes FA, Allison MAK, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013 Oct; 14(11):1121-1128.
    View in: PubMed
    Score: 0.050
  3. Sedlacek SM. First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine. Oncology. 1993 Apr; 50 Suppl 1:16-21.
    View in: PubMed
    Score: 0.048
  4. Sedlacek SM. Salvage therapy for metastatic disease. Semin Oncol. 1990 Aug; 17(4 Suppl 7):45-9.
    View in: PubMed
    Score: 0.040
  5. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010 Jun 20; 28(18):2958-65.
    View in: PubMed
    Score: 0.040
  6. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 01; 23(16):3686-96.
    View in: PubMed
    Score: 0.028
  7. Leonard CE, Wood ME, Zhen B, Rankin J, Waitz DA, Norton L, Howell K, Sedlacek S. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol. 1995 Dec; 13(12):2906-15.
    View in: PubMed
    Score: 0.015
  8. O'Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Brownstein C, Hoersch S, Blum JL, Jones S. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin Cancer Res. 2015 Oct 01; 21(19):4305-11.
    View in: PubMed
    Score: 0.014
  9. Sedlacek SM, Horwitz KB. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids. 1984 Dec; 44(6):467-84.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)